Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/27245
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Salvaris R. | en |
dc.contributor.author | Opat S. | en |
dc.date.accessioned | 2021-05-14T09:07:57Z | en |
dc.date.available | 2021-05-14T09:07:57Z | en |
dc.date.copyright | 2021 | en |
dc.date.created | 20210220 | en |
dc.date.issued | 2021-02-20 | en |
dc.identifier.citation | Future Oncology. 17 (4) (pp 371-387), 2021. Date of Publication: February 2021. | en |
dc.identifier.issn | 1479-6694 | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/27245 | en |
dc.description.abstract | In the last decade, the treatment of chronic lymphocytic leukemia (CLL) has shifted away from chemoimmunotherapy toward targeted novel agents such as small molecule inhibitors and antibodies. Here, we give an overview of the pharmacology of venetoclax and obinutuzumab and the evidence from early phase to Phase III trials that have shaped how they are used in the treatment of CLL. Venetoclax, an oral anti-apoptotic BCL-2 inhibitor, in combination with a CD20 antibody has shown superiority to chemoimmunotherapy in treatment-naive and relapsed/refractory CLL. Obinutuzumab is a novel anti-CD20 monoclonal antibody that has been safely combined with novel agents including venetoclax and Bruton tyrosine kinase inhibitors and has shown superiority over rituximab when combined with chlorambucil.Copyright © 2020 Future Medicine Ltd. | en |
dc.language | English | en |
dc.language | en | en |
dc.publisher | Future Medicine Ltd. | en |
dc.relation.ispartof | Future Oncology | en |
dc.title | An update of venetoclax and obinutuzumab in chronic lymphocytic leukemia. | en |
dc.type | Article | en |
dc.identifier.affiliation | Haematology | en |
dc.identifier.doi | http://monash.idm.oclc.org/login?url= | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.2217/fon-2020-0640 | en |
dc.publisher.place | United Kingdom | en |
dc.identifier.pubmedid | 33064021 [http://www.ncbi.nlm.nih.gov/pubmed/?term=33064021] | en |
dc.identifier.source | 634113507 | en |
dc.identifier.institution | (Salvaris, Opat) Department of Haematology, Monash Health, 246 Clayton Rd, Clayton, VIC 3168, Australia (Salvaris) School of Clinical Sciences at Monash Health, Monash University, Wellington Rd, Clayton, VIC 3800, Australia | en |
dc.description.address | R. Salvaris | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2021 Elsevier B.V., All rights reserved. | en |
dc.subect.keywords | anti-CD20 monoclonal antibodies BCL2 inhibitors chronic lymphocytic leukemia obinutuzumab venetoclax | en |
dc.identifier.authoremail | Salvaris R.; ross.salvaris@monashhealth.org | en |
dc.identifier.affiliationmh | (Salvaris, Opat) Department of Haematology, Monash Health, 246 Clayton Rd, Clayton, VIC 3168, Australia | - |
dc.identifier.affiliationmh | (Salvaris) School of Clinical Sciences at Monash Health, Monash University, Wellington Rd, Clayton, VIC 3800, Australia | - |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | Article | - |
crisitem.author.dept | Haematology | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.